Palisade Bio (PALI) Fundamental Analysis: Revenue, Earnings & Valuation

1.62 / 10

Underperform

Fundamental analysis rates PALI as Underperform (1.6/10). Strengths include high inventory turnover, strong fixed‑asset utilization and rapid revenue growth. Weaknesses are low gross margin, high cost‑of‑sales ratio and elevated income‑tax‑to‑profit, rendering the profile defensive.

Analysis Checks(4/6)

Total operating revenue (YoY growth rate %)

Value388.39

Score3/3

Weight-45.73%

1M Return1.54%

Inventory turnover ratio

Value23.18

Score2/3

Weight33.01%

1M Return-1.21%

Gross profit margin (%)

Value26.01

Score1/3

Weight16.64%

1M Return-0.63%

Income tax / Total profit (%)

Value15.33

Score1/3

Weight13.54%

1M Return-0.50%

Fixed assets turnover ratio

Value3878.11

Score3/3

Weight-30.24%

1M Return1.06%

Cost of sales ratio (%)

Value83.38

Score2/3

Weight112.78%

1M Return-4.42%

Is PALI undervalued or overvalued?

PALI scores 1.62/10 on fundamentals and holds a Premium valuation at present. Backed by its -24.52% ROE, 0.00% net margin, -18.58 P/E ratio, 2.41 P/B ratio, and 97.06% earnings growth, these metrics solidify its Underperform investment rating.